ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Tata Memorial Hospital at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Tata Memorial Hospital takes part in 8 sessions at ESMO 2026 in Madrid. Its work spans gastrointestinal, breast, and oral cancers, with a focus on treatment choices and outcomes. It compares chemotherapy approaches for advanced pancreatic cancer and treatment regimens before surgery for oral cancer.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Cancer treatment and research hospital in Mumbai, India, run by Tata Memorial Centre, a government-aided cancer centre under the Department of Atomic Energy.
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Predictive genomic profiling for advanced oral cancer
ePoster session 23
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Talk
Fri Oct 23
17:15–17:35
Optimized approaches to checkpoint inhibitors
The exorbitant costs of cancer care: What can we do?
Talk
Sun Oct 25
10:35–10:55
Neoadjuvant therapy for HER2+ breast cancer
Optimising treatment for HER2+ early breast cancer
Breast cancer
Poster
Sun Oct 25
12:00–12:45
Poster
Sun Oct 25
12:00–12:45
Talk
Mon Oct 26
10:52–11:07
From evidence to access: Operationalising adaptation at scale
When standards are unsustainable: Redefining cancer treatment under resource pressure

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Tata Memorial Hospital

Tell us what you sell and we’ll find the people at Tata Memorial Hospital most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction